By Will Feuer
Omeros said it is discontinuing its late-stage clinical trial evaluating its narsoplimab drug for the treatment of immunoglobulin A nephropathy after interim data from the trial failed to meet its primary endpoint.
The clinical-stage biopharmaceutical company said it will not submit an application for approval of narsoplimab in the indication that the trial was evaluating.
Topline results from the trial showed that narsoplimab didn’t achieve statistically significant improvement over placebo.
“We will conduct more detailed analyses of the data to understand better the outsized placebo effect and the overall trial results and to try to identify useful biomarkers,” said Omeros Chief Executive Gregory Demopulos.
He added that the funds earmarked for the continuation for the trial will be redirected.
Write to Will Feuer at [email protected]
Read the full article here
